Posted by Michael Wonder on 11 Feb 2021
Seagen and Genmab submit tisotumab vedotin biologics license application to the U.S. FDA for patients with recurrent or metastatic cervical cancer
11 February 2021 - Submission based on positive pivotal innovaTV 204 trial results presented at the European Society of Medical Oncology Virtual Congress 2020.
Seagen and Genmab today announced the submission of a biologics license application to the U.S. FDA seeking accelerated approval for tisotumab vedotin.
